Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Clinical genitourinary cancer·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

Chemoradiotherapy for anal canal cancers: Does the choice of boost technique matter?

Journal of contemporary brachytherapy·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same author

Beyond GnRH analogues: The renaissance of estrogens in prostate cancer management.

The French journal of urology·2026

Related Experiment Video

Updated: Jul 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Prostate cancer and chemotherapy].

Gwenaelle Gravis1, Naji Salem, Franck Bladou

  • 1Institut Paoli-Calmettes, Marseille.

Bulletin Du Cancer
|September 13, 2007
PubMed
Summary

Androgen deprivation therapy for metastatic prostate cancer offers initial symptom relief but often leads to treatment-resistant disease. Docetaxel chemotherapy significantly improves survival and quality of life for patients with hormone-refractory prostate cancer (HRPC).

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Experiment Videos

Last Updated: Jul 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Area of Science:

  • Oncology
  • Urology

Background:

  • Androgen deprivation therapy (ADT) is a primary treatment for metastatic prostate cancer, inducing initial symptom palliation and tumor regression.
  • Most patients eventually develop hormone-refractory prostate cancer (HRPC), characterized by disease progression and poor prognosis.
  • Current treatments like mitoxantrone chemotherapy offer palliation but not survival benefits.

Purpose of the Study:

  • To review the efficacy of docetaxel chemotherapy in patients with hormone-refractory prostate cancer (HRPC).
  • To discuss emerging therapeutic strategies targeting angiogenesis, apoptosis, and signal transduction pathways.
  • To evaluate the potential role of neoadjuvant or adjuvant chemotherapy in high-risk prostate cancer settings.

Main Methods:

  • Review of data from two large randomized trials evaluating docetaxel in HRPC.
  • Analysis of current clinical trial data for novel therapeutic agents.
  • Assessment of safety and feasibility data for neoadjuvant and adjuvant chemotherapy.

Main Results:

  • Docetaxel-based chemotherapy demonstrated a significant survival benefit in HRPC patients, reducing the risk of death by 21-24%.
  • Docetaxel treatment led to significant improvements in symptom palliation and quality of life.
  • Neoadjuvant or adjuvant chemotherapy has shown to be safe and feasible in high-risk populations, though further research is needed.

Conclusions:

  • Docetaxel chemotherapy is a key treatment for HRPC, improving survival and quality of life.
  • Novel agents targeting specific molecular pathways are under investigation to further enhance treatment outcomes.
  • Prospective randomized trials are crucial to define the optimal use of chemotherapy in the adjuvant or neoadjuvant settings for high-risk prostate cancer.